Improved Survival in Subset of Advanced Pancreatic Cancer
Adding nimotuzumab to gemcitabine significantly improved survival outcomes in a subset of patients with KRAS wild-type advanced pancreatic cancer.
United States Shukui Qin Cathy Eng Julier Gralow American Society Of Clinical Oncology Chinese National Medical Products Administration
Source: medscape.com